Findings

What do systematic reviews say?

10 questions · 10 findings · 2 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 30%Low 7 · 70%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Very potent vs potent topical corticosteroid · Local adverse events: skin thinning; end of treatment (day 11‐day 22)
  Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 233 participants
  Very low
Direct match · question page
- Very potent vs potent topical corticosteroid · Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks)
  Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
  OR 0.53 [0.13, 2.09]
  3 studies · 243 participants
  Low
Direct match · question page
- Very potent vs potent topical corticosteroid · Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8)
  Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 116 participants
  Very low
Direct match · question page
- Very potent vs potent topical corticosteroid · Systemic adverse events: abnormal cortisol
  Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 117 participants
  Very low
Direct match · question page
- Potent/very potent topical corticosteroids vs no topical corticosteroids · Orofacial cleft
  Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
  RR 1.5
  36348 participants
  Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Congenital abnormality · pregnant women

Potent/very potent topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 0.56
9342 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Orofacial cleft · pregnant women

Potent/very potent topical corticosteroids may leads to higher orofacial cleft compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.5
36348 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Low birthweight · pregnant women

Potent/very potent topical corticosteroids may leads to higher low birth weight compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.58
47651 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Preterm birth · pregnant women

Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.05
47651 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Foetal death · pregnant women

Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.14
37086 participants
Low

Potent/very potent topical corticosteroids vs no topical corticosteroids

Low Apgar score · pregnant women

Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).

1 finding from 1 review

Safety of topical corticosteroids in pregnancy 2015 · Cochrane Headline outcomes only
RR 1.03
7514 participants
Low

Very potent vs potent topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema

Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
OR 0.53 [0.13, 2.09]
3 studies · 243 participants
Low

Very potent vs potent topical corticosteroid

Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 116 participants
Very low

Very potent vs potent topical corticosteroid

Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema

It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 233 participants
Very low

Very potent vs potent topical corticosteroid

Systemic adverse events: abnormal cortisol · adults with eczema

1 finding from 1 review

Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Very low